EGFR and non-small cell lung carcinoma: Moreover, data from the CTONG-0803 trial (25), a phase II, open-label prospective study that evaluated the efficiency of erlotinib in NSCLC with BM, showed that EGFR-positive patients had longer PFS than those with EGFR-negative patients (15.2 months vs. 4.4 months, P = 0.02).